We agree with Dr Mackenzie that there is a substantial difference between patients with DLB and AD in terms of the degree of brain inflammation, as noted in his recent report.1 Patients with DLB have a much reduced inflammatory response, and, if anti-inflammatory medications target brain inflammation, patients with AD would be expected to show greater benefit than those with DLB.
Halliday G, Shepherd C. In reply. Arch Neurol. 2001;58(3):519–520. doi:
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.